Fixed combination of levocetirizine and montelukast in the treatment of allergic rhinitis


DOI: https://dx.doi.org/10.18565/therapy.2023.8.173-178

Bolieva L.Z., Moulid A., Basieva A.T.

1) North Ossetian State Medical Academy of the Ministry of Healthcare of Russia, Vladikavkaz; 2) H.M. Berbekov Kabardino-Balkarian State University, Nalchik
Abstract. The main goals of allergic rhinitis (AR) therapy are to relief symptoms, achieve and maintain control, reduce the risk of complications and improve the quality of life. AR treatment requires complex approach. When choosing pharmacotherapy, the severity of the disease, the main symptoms and their severity, individual social and psychological characteristics and preferences of the patient, concomitant pathology are taken into account. The key role of histamine and cysteine leukotrienes in the pathogenesis of AR determines the widespread use of blockers of H1-histamine receptors and leukotriene receptor antagonists in the treatment of this pathology. As levocetirizine is an effective second-generation H1-blocker, montelukast is the main representative of the class of leukotriene receptor antagonists, the use of a fixed combination of levocetirizine and montelukast seems to be a rational strategy for the treatment of AR in terms of increasing its effectiveness and patient compliance.
Keywords: leukotriene receptor antagonists, H1-histamine receptor blockers, levocetirizine, montelukast, allergic rhinitis
Read entire article

Literature

1. Клинические рекомендации. Аллергический ринит. Российская ассоциация аллергологов и клинических иммунологов, Национальная медицинская ассоциация оториноларингологов, Союз педиатров России. Рубрикатор клинических рекомендаций Минздрава России. 2020. ID: 261. Доступ: http://cr.rosminzdrav.ru/schema/261_1 (дата обращения – 01.06.2023). [Clinical guidelines. Allergic rhinitis. Russian Association of Allergists and Clinical Immunologists, National Medical Association of Otorhinolaryngologists, Russian Union of Pediatricians. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2020. ID: 261. URL: http://cr.rosminzdrav.ru/schema/261_1 (date of access – 01.06.2023) (In Russ.)].


2. Астафьева Н.Г., Баранов А.А., Вишнева Е.А. с соавт. Аллергический ринит. Российский аллергологический журнал. 2022; 19(1): 100–141. [Astafieva N.G., Baranov A.A., Vishneva E.A. et al. Allergic rhinitis. Rossiyskiy allergologicheskiy zhurnal = Russian Journal of Allergology. 2022; 19(1): 100–141 (In Russ.)]. http://dx.doi.org/10.36691/RJA1524. EDN: WGQIPE.


3. Хаитов М.Р., Намазова-Баранова Л.С., Чучалин А.Г. с соавт. ARIA 2016: Современные направления оказания медицинской помощи больным аллергическим ринитом в свете требований прецизионной медицины. Российский аллергологический журнал. 2017; 14(3): 46–54. [Khaitov M.R., Namazova-Baranova L.S., Chuchalin A.G. et al. ARIA 2016: Integrated care pathways for predictive medicine across the life cycle. Rossiyskiy allergologicheskiy zhurnal = Russian Journal of Allergology. 2017; 14(3): 46–54 (In Russ.)]. EDN: ZFUACR.


4. Brozek J.L., Bousquet J., Baena-Cagnani C.E. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2017 revision. J Allergy Clin Immunol. 2017; 140(4): 950–58. http://dx.doi.org/10/1016/j/jaci.2017.03.050.


5. Bousquet J., Khaltaev N., Cruz A.A. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008; 63 Suppl 86: 8–160. http://dx.doi.org/10.1111/j.1398-9995.2007.01620.x.


6. Хаитов М.Р., Намазова-Баранова Л.С., Ильина Н.И. с соавт. ARIA 2019: алгоритмы оказания помощи при аллергическом рините в России. Российский аллергологический журнал. 2020; 17(1): 7–22. [Khaitov M.R., Namazova-Baranova L.S, Ilyina N.I. et al. 2019 ARIA: Care pathways for allergic rhinitis in Russia. Rossiyskiy allergologicheskiy zhurnal = Russian Journal of Allergology. 2020; 17(1): 7–22 (In Russ.)]. http://dx.doi.org/10.36691/RAJ.2020.17.1.001. EDN: HHBTEI.


7. Wise S.K., Lin S.Y., Toskala E. et al. International consensus statement on allergy and rhinology: Allergic rhinitis – executive summary. Int Forum Allergy Rhinol. 2018; 8(2): 85–107. http://dx.doi.org/10.1002/alr.22073.


8. Global atlas of allergy. Editors: Cezmi A. Akdis, Ioana Agache. Published by the European Academy of Allergy and Clinical Immunology. 2014; 388 pp. http://dx.doi.org/10.5167/uzh-140934.


9. World Allergy Organization. Pawankar R., Canonica G.W., Holgate S.T. et al. The World Allergy Organization White Book on Allergy. 2013; 248 pp. URL: https://www.worldallergy.org/wao-white-book-on-allergy (date of access – 01.06.2023).


10. Corren J. The impact of allergic rhinitis on bronchial asthma. J Allergy Clin Immunol. 1998; 101(2 Pt 2): 352–56. http://dx.doi.org/10.1016/s0091-6749(98)70218-0.


11. Tohidinik H.R., Mallah N., Takkouche B. History of allergic rhinitis and risk of asthma; A systematic review and meta-analysis. World Allergy Organ J. 2019; 12(10): 100069. http://dx.doi.org/10.1016/j.waojou.2019.100069.


12. Akdis C.A., Jutel M., Akdis M. Regulatory effects of histamine and histamine receptor expression in human allergic immune responses. Chem Immunol Allergy. 2008; (94): 67–82. http://dx.doi.org/10.1159/000154858.


13. Thangam E.B., Jemima E.A., Singh H. et al. The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: The hunt for new therapeutic targets. Front Immunol. 2018; (9): 1873. http://dx.doi.org/10.3389/fimmu.2018.01873.


14. Peters-Golden M., Gleason M.M., Togias A. Cysteinyl leukotrienes: Multi-functional mediators in allergic rhinitis. Clin Exp Allergy. 2006; 36(6): 689–703. http://dx.doi.org/10.1111/j.1365-2222.2006.02498.x.


15. Jo-Watanabe A., Okuno T., Yokomizo T. The role of leukotrienes as potential therapeutic targets in allergic disorders. Int J Mol Sci. 2019; 20(14): 3580. http://dx.doi.org/10.3390/ijms20143580.


16. Sokolowska M., Rovati G.E., Diamant Z. et al. Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I. Allergy. 2021; 76(1): 114–30. http://dx.doi.org/10.1111/all.14295.


17. Samuchiwal S.K., Boyce J.A. Role of lipid mediators and control of lymphocyte responses in type 2 immunopathology. J Allergy Clin Immunol. 2018; 1419(4): 1182–90. http://dx.doi.org/10.1016/j.jaci.2018.02.006.


18. Liu M., Yokomizo T. The role of leukotrienes in allergic diseases. Allergol Int. 2015; 64(1): 17–26. http://dx.doi.org/10.1016/j.alit.2014.09.001


19. Ulrik C.S., Diamant Z. Add-on montelukast to inhaled corticosteroids protects against excessive airway narrowing. Clin Exp Allergy. 2010; 40(4): 576–81. http://dx.doi.org/10.1111/j.1365-2222.2010.03447.x.


20. Ненашева Н.М. Терапия аллергического ринита: какой антигистаминный препарат выбрать? РМЖ. 2015; 23(9): 514–552. [Nenasheva N.M. Therapy of allergic rhinitis: which antihistamine to choose? Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2015; 23(9): 514–552 (In Russ.)]. EDN: UBLUSJ.


21. Носуля Е.В., Ким И.А., Лучшева Ю.В., Изотова Г.Н. Коморбидность аллергического ринита – актуальность антигистаминной терапии в повседневной практике. Профилактическая медицина. 2019; 22(4): 124–128. [Nosulya E.V., Kim I.A., Luchsheva Yu.V., Izotova G.N. Comorbidity of allergic rhinitis: Relevance of antihistamine therapy in daily practice. Profilakticheskaya meditsina = Preventive Medicine. 2019; 22(4): 124–128 (In Russ.). http://dx.doi.org/10.17116/profmed201922041124. EDN: DCPKPT.


22. Ciprandi G., Cirillo I., Vizzaccaro A., Tosca M.A. Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: A pilot study. Clin Exp Allergy. 2004; 34(6): 958–64. http://dx.doi.org/10.1111/j.1365-2222.2004.01960.x.


23. Walsh G.M. Levocetirizine: An update. Curr Med Chem. 2006; 13(22): 2711–15. http://dx.doi.org/10.2174/092986706778201594.


24. Holgate S., Powell R., Jenkins M., Ali O. A treatment for allergic rhinitis: A view on the role of levocetirizine. Curr Med Res Opin. 2005; 21(7): 1099–106. http://dx.doi.org/10.1185/030079905X53298.


25. Bachert C. A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. Clin Ther. 2009; 31(5): 921–44. http://dx.doi.org/10.1016/j.clinthera.2009.05.017.


26. Nayak A., Langdon R.B. Montelukast in the treatment of allergic rhinitis: An evidence-based review. Drugs. 2007; 67(6): 887–901. http://dx.doi.org/10.2165/00003495-200767060-00005.


27. Razi С., Bakirtas А., Harmanci К. et al. Effect of montelukast on symptoms and exhaled nitric oxide levels in 7- to 14-year-old children with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2006; 97(6): 767–74. http://dx.doi.org/10.1016/S1081-1206(10)60968-4.


28. Virchow J.C., Mehta A., Ljungblad L., Mitfessel H. A subgroup analysis of the MONICA study: A 12-month, open-label study of add-on montelukast treatment in asthma patients. J Asthma. 2010 Nov; 47(9): 986–93. http://dx.doi.org/10.1080/02770903.2010.494753.


29. Tintinger G.R., Feldman C., Theron A.J., Anderson R. Montelukast: more than a cysteinyl leukotriene receptor antagonist? ScientificWorldJournal. 2010; (10): 2403–13. http://dx.doi.org/10.1100/tsw.2010.229.


30. Meltzer E.O., Malmstrom K., Lu S. et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebocontrolled clinical trial. J Allergy Clin Immunol. 2000; 105(5): 917–22. http://dx.doi.org/10.1067/mai.2000.106040.


31. Ciebiada M., Gorska-Ciebiada M., DuBuske L.M., Gorski P. Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. Ann Allergy Asthma Immunol. 2006; 97(5): 664–71. http://dx.doi.org/10.1016/S1081-1206(10)61098-8.


32. Kurowski M., Kuna P., Gorski P. Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergy inflammation. Allergy. 2004; 59(3): 280–88. http://dx.doi.org/10.1046/j.1398-9995.2003.00416.x.


33. Bylappa K., Wilma D.S.C.R. Evaluation of efficacy of fixed dose combination of montelukast and levocetirizine compared to monotherapy of montelukast and levocetirizine in patients with seasonal allergic rhinitis. Int J Otorhinolaryngol Head Neck Surg. 2018; (4): 467–72. http://dx.doi.org/10.18203/issn.2454-5929.ijohns20180708.


34. Gupta V., Matreja P.S. Efficacy of montelukast and levocetirizine as treatment for allergic rhinitis. J Allergy Ther. 2010; (1): 103. https://dx.doi.org/10.4172/2155-6121.1000103.


35. Kim M.K., Lee S.Y., Park H.S. et al. A randomized, multicenter, double-blind, phase iii study to evaluate the efficacy on allergic rhinitis and safety of a combination therapy of montelukast and levocetirizine in patients with asthma and allergic rhinitis. Clinical Therapeutics. 2018; 40(7): 1096–107e1. https://dx.doi.org/10.1016/j.clinthera.2018.04.021.


36. Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению лекарственного препарата Монтрал МЛ. РУ: ЛП-005150. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=8cafc881-7c95-41f7-bdad-bbf080afd5c8 (дата обращения – 01.06.2023). [[State Register of Medicines of the Ministry of Healthcare of Russia. Instructions for medical use of the medicinal product Montral ML. Registration certificate: ЛП-005150. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=8cafc881-7c95-41f7-bdad-bbf080afd5c8 (date of access – 01.06.2023) (In Russ.)].


37. Шогенова М.С., Хутуева С.Х., Шогенова Л.С. Современные подходы к патогенетической терапии аллергического ринита. Фармакология & фармакотерапия. 2021; (4): 36–43. [Shogenova M.S., Khutueva S.Kh., Shogenova L.S. Modern approaches to pathogenetic therapy of allergic rhinitis. Farmakologiya & farmakoterapiya = Pharmacology & Pharmacotherapy. 2021; (4): 36–43 (In Russ.)]. https://dx.doi.org/10.46393/2713-2129_2021_4_36_42. EDN: ZEJPOP.


About the Autors

Laura Z. Bolieva, MD, professor, head of the Department of pharmacology with clinical pharmacology, North Ossetian State Medical Academy of the Ministry of Healthcare of Russia. Address: 362019, Vladikavkaz, 40 Pushkinskaya Str. E-mail: bolievalz@mail.ru. ORCID: https://orcid.org/0000-0002-3763-8994
Ahmed Moulid, assistant at the Department of faculty therapy of the Faculty of general medicine, H.M. Berbekov Kabardino-Balkarian State University. Address: 360004, Nalchik, 173 Chernyshevskogo Str. E-mail: mowlidkudar@gmail.com. ORCID: https://orcid.org/0009-0008-7579-784
Amina T. Basieva, 5th year student of North Ossetian State Medical Academy of the Ministry of Healthcare of Russia. Address: 362019, Vladikavkaz, 40 Pushkinskaya Str. E-mail: amina.basieva@bk.ru


Similar Articles

Back to Content

Бионика Медиа